Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Breast Cancer
100%
Insulin-like Growth Factor 1 Receptor (IGF1R)
100%
Temsirolimus
100%
Phase I Trial
100%
Cixutumumab
100%
Maximum Tolerated Dose
75%
Serum Levels
50%
Insulin-like Growth factor-1
50%
Insulin-like Growth Factor Binding protein-3 (IGFBP-3)
50%
Comorbid Conditions
25%
Hyperglycemia
25%
Disease Progression
25%
Antitumor Activity
25%
Adverse Events
25%
Anemia
25%
Neutropenia
25%
Mammalian Target of Rapamycin (mTOR)
25%
Breast Cancer
25%
Dose-limiting Toxicity
25%
Pharmacodynamic Interactions
25%
Phase II Study
25%
Dose Effect
25%
Am(III)
25%
Thrombocytopenia
25%
Metastatic Disease
25%
Prior Chemotherapy
25%
Stable Disease
25%
Chemotherapy Regimen
25%
Tumor Cell Proliferation
25%
Objective Response
25%
MTOR Inhibitor
25%
Estrogen Receptor-positive
25%
Mucositis
25%
Insulin-like Growth Factor 2 (IGF2)
25%
3-phase
25%
Phase I Design
25%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Temsirolimus
100%
Receptor Antibody
100%
Somatomedin
100%
Cixutumumab
100%
Maximum Tolerated Dose
75%
Hyperglycemia
25%
Receptor
25%
Tumor Growth
25%
Malignant Neoplasm
25%
Anemia
25%
Neutropenia
25%
Adverse Event
25%
Pharmacodynamics
25%
Chemotherapy
25%
Breast Cancer
25%
Estrogen Receptor
25%
Disease Exacerbation
25%
Thrombocytopenia
25%
Antitumor Activity
25%
Patient History of Chemotherapy
25%
Preclinical Study
25%
Mammalian Target of Rapamycin
25%
Mammalian Target of Rapamycin Inhibitor
25%
Mucosa Inflammation
25%
Protein Kinase B
25%
Phase I Trials
25%
Diseases
25%